Open access · CC-BY
via OpenAlex
Allogeneic Mesenchymal Stem Cells as a Treatment for Aging Frailty
Bryon A. Tompkins, Ana Marie Landin, Victoria Florea, Makoto Natsumeda, Angela Castellanos Rieger, Wayne Balkan, Ivonne Hernandez Schulman, Joshua M. Hare
InTech eBooks · 2017 · ▲ 3 citations
Abstract
As life expectancy is projected to increase in the ensuing decades, individuals of older age continue to exceed the previous generation’s lifespan. Advancing age is associated with a reduction in physical and mental functional capacity, and chronic inflammation is a major factor contributing to this decline. A heightened inflammatory state can lead to exhaustion, weakness, weight loss, slow gate speed, and an overall decrease in activity level. These phenotypes define the onset of the disease process known as frailty. Frailty is a growing epidemic, which severely undermines a person’s ability to deal with outside stressors, and increases their rate of hospitalization, institutionalization, and mortality. Current interventions focus on preventative care by improving exercise capacity, strength, nutritional supplementation, diet, and mobility. However, a biological cure has heretofore remained elusive. Here, we introduce the novel therapeutic principle that mesenchymal stem cell (MSC) therapy may represent a safe, practical, and efficacious both the treatment and prevention of frailty in individuals of advancing age. To date, a phase I safety trial reveals an excellent safety profile and suggests that mesenchymal stem cells can ameliorate signs and symptoms of frailty. These early studies lay the groundwork for future large-scale clinical trials of this exciting and novel therapeutic concept that has the potential to expand health span in the aging population.
◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:
Provenance
- Source
- OpenAlex
- DOI
- 10.5772/intechopen.69194
- Canonical
- link ↗
- Fetched
- 2026-10-06 MST
Cite this
APA
Tompkins, B.A., Landin, A.M., Florea, V., Natsumeda, M., Rieger, A.C., Balkan, W., Schulman, I.H., & Hare, J.M. (2017). Allogeneic Mesenchymal Stem Cells as a Treatment for Aging Frailty. <em>InTech eBooks</em>. https://doi.org/10.5772/intechopen.69194
Vancouver
Tompkins BA, Landin AM, Florea V, Natsumeda M, Rieger AC, Balkan W, et al. Allogeneic Mesenchymal Stem Cells as a Treatment for Aging Frailty. InTech eBooks. 2017. doi:10.5772/intechopen.69194.
BibTeX
@article{bryon2017Alloge,
title = {Allogeneic Mesenchymal Stem Cells as a Treatment for Aging Frailty},
author = {Bryon A. Tompkins and Ana Marie Landin and Victoria Florea and Makoto Natsumeda and Angela Castellanos Rieger and Wayne Balkan and Ivonne Hernandez Schulman and Joshua M. Hare},
journal = {InTech eBooks},
year = {2017},
doi = {10.5772/intechopen.69194},
}
Research neighborhood
References, citing works, and semantically nearest findings. Click a node to open it.
Related findings
Mechanisms of Ageing and Development 2019
Citation only
Attenuation of frailty in older adults with mesenchymal stem cells
World journal of stem cells 2026
Open access · OA
Aging puzzle: A closer look on the complex dilemma of autologous stem cell therapy.
Theranostics 2021
Open access · CC-BY
Application of mesenchymal stem cell therapy for aging frailty: from mechanisms to therapeutics
Frontiers in Aging 2023
Open access · CC-BY
Recent clinical trials with stem cells to slow or reverse normal aging processes
Journal of sport and health science/Journal of Sport and Health Science 2025
Open access · CC-BY
Exercise attenuates the hallmarks of aging: Novel perspectives
Hillel Yaffe Medical Center 2013
Open access · US-GOV